4.3 Diabetes Mellitus: Diagnosis, Complications & Management
Key Takeaways
- Diabetes Mellitus diagnostic thresholds: Fasting Plasma Glucose ≥126 mg/dL, 2-hour OGTT ≥200 mg/dL, HbA1c ≥6.5%, or Random Plasma Glucose ≥200 mg/dL with classic hyperglycemic symptoms.
- Diabetic Ketoacidosis (DKA) is defined by hyperglycemia (>250 mg/dL), high anion gap metabolic acidosis (pH <7.30, HCO3 <18 mEq/L), and serum/urine hyperketonemia, requiring IV normal saline, regular insulin, and strict potassium repletion.
- Hyperosmolar Hyperglycemic State (HHS) presents with extreme hyperglycemia (>600 mg/dL), high effective serum osmolality (>320 mOsm/kg), and minimal acidosis, requiring aggressive fluid resuscitation.
- Metformin is the initial drug of choice for Type 2 Diabetes but is contraindicated when eGFR <30 mL/min/1.73 m² due to lactic acidosis risk.
- SGLT2 inhibitors (Empagliflozin, Dapagliflozin) provide proven cardiorenal protection and reduce heart failure hospitalizations, while GLP-1 receptor agonists (Semaglutide, Liraglutide) reduce major adverse cardiovascular events (MACE) and promote significant weight loss.
Diabetes Mellitus: Diagnosis, Complications & Management
Diabetes Mellitus is one of the most frequently tested topics in UPSC CMS General Medicine. Candidates must master diagnostic cut-offs, acute crisis management protocols (DKA vs HHS), microvascular organ protection, and guideline-directed pharmacotherapy.
1. Diagnostic Criteria & Screening Guidelines
According to the American Diabetes Association (ADA) guidelines, the diagnosis of Diabetes Mellitus requires fulfilling any one of the four standardized criteria:
| Diagnostic Category | Fasting Plasma Glucose (FPG) | 2-Hour OGTT (75g glucose) | HbA1c Level | Random Plasma Glucose |
|---|---|---|---|---|
| Normal | <100 mg/dL (5.6 mmol/L) | <140 mg/dL (7.8 mmol/L) | <5.7% | — |
| Prediabetes | 100–125 mg/dL (IFG) | 140–199 mg/dL (IGT) | 5.7% – 6.4% | — |
| Diabetes Mellitus | ≥126 mg/dL (7.0 mmol/L) | ≥200 mg/dL (11.1 mmol/L) | ≥6.5% (NGSP certified) | ≥200 mg/dL + Classic Symptoms |
Diagnostic Rules:
- Fasting is defined as no caloric intake for at least 8 hours.
- In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis or classic symptoms of polyuria, polydipsia, unexplained weight loss), diagnosis requires two abnormal test results from the same sample or two separate test samples.
2. Acute Hyperglycemic Crises: DKA vs. HHS
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) are life-threatening endocrine emergencies. DKA occurs predominantly in Type 1 DM due to absolute insulin deficiency, whereas HHS occurs in Type 2 DM (especially elderly, impaired thirst response) due to relative insulin deficiency.
| Clinical Parameter | Diabetic Ketoacidosis (DKA) | Hyperosmolar Hyperglycemic State (HHS) |
|---|---|---|
| Primary Population | Type 1 Diabetes Mellitus | Type 2 Diabetes Mellitus (Elderly) |
| Blood Glucose | >250 mg/dL (usually 300–600 mg/dL) | >600 mg/dL (often >1000 mg/dL) |
| Arterial pH | <7.30 (Mild 7.25–7.30, Mod 7.00–7.24, Severe <7.00) | >7.30 (Normal or mild acidosis) |
| Serum Bicarbonate | <18 mEq/L (Severe <10 mEq/L) | >18 mEq/L |
| Ketones (Serum/Urine) | Strongly Positive (Beta-hydroxybutyrate) | Absent or Trace |
| Serum Osmolality | Variable (<320 mOsm/kg) | >320 mOsm/kg (Extreme Hyperosmolality) |
| Anion Gap | High Anion Gap (>12 mEq/L) | Variable / Normal |
| Respiration | Kussmaul breathing (deep, rapid) with fruity acetone odor | Normal or shallow |
| Mental Status | Alert to lethargic | Stupor or Coma |
Acute Management Protocol for DKA
- Fluid Resuscitation (First Priority): 0.9% Normal Saline (1.0–1.5 L in the 1st hour). Switch to 0.45% NaCl once corrected serum sodium is normal or high. Add 5% Dextrose when blood glucose reaches 200–250 mg/dL to prevent cerebral edema and allow continued insulin for ketoacidosis clearance.
- Insulin Therapy: IV Regular Insulin 0.1 Units/kg bolus, followed by 0.1 Units/kg/hour continuous infusion (or 0.14 U/kg/h without bolus). Target BG reduction rate: 50–75 mg/dL per hour.
- Potassium Repletion (CRITICAL):
- Check K⁺ before initiating insulin.
- If K⁺ <3.3 mEq/L: HOLD INSULIN and give IV KCl (20–30 mEq/h) until K⁺ >3.3 mEq/L (insulin shifts K⁺ into cells and can trigger fatal arrhythmia).
- If K⁺ 3.3–5.3 mEq/L: Add 20–30 mEq K⁺ per liter of IV fluid to maintain serum K⁺ between 4.0–5.0 mEq/L.
- If K⁺ >5.3 mEq/L: Do not add K⁺; recheck every 2 hours.
- Bicarbonate: Indicated ONLY if pH <6.90.
3. Chronic Microvascular & Macrovascular Complications
A. Diabetic Retinopathy
- Non-Proliferative Diabetic Retinopathy (NPDR): Microaneurysms (earliest clinical sign), hard exudates (lipid deposits), cotton-wool spots (nerve fiber layer microinfarctions), intraretinal hemorrhages ("dot and blot").
- Proliferative Diabetic Retinopathy (PDR): Marked by Neovascularization (formation of new vessel growth driven by retinal ischemia and VEGF elevation). Complications: Vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma.
- Screening: Type 1 DM (5 years after diagnosis); Type 2 DM (at diagnosis).
- Treatment: Anti-VEGF intravitreal injections (Ranibizumab, Aflibercept) and Panretinal Photocoagulation (PRP).
B. Diabetic Nephropathy
- Progression: Glomerular hyperfiltration → Moderately increased albuminuria (30–300 mg/day) → Severely increased albuminuria (>300 mg/day) → Progressive GFR decline.
- Histology: Diffuse glomerulosclerosis and pathognomonic Kimmelstiel-Wilson nodules (nodular intercapillary glomerulosclerosis, PAS-positive).
- Treatment: First-line agents to retard progression are ACE inhibitors / ARBs (reduce intraglomerular pressure by dilating efferent arterioles) and SGLT2 inhibitors.
C. Diabetic Neuropathy
- Distal Symmetric Polyneuropathy: Most common form. Progressive sensory loss in a classic "glove-and-stocking" distribution (vibration and position sense affected first, followed by pain and temperature).
- Autonomic Neuropathy: Resting tachycardia, orthostatic hypotension, gastroparesis (treated with Metoclopramide or Erythromycin), neurogenic bladder, erectile dysfunction.
- Neuropathic Pain Pharmacotherapy: First-line agents include Pregabalin, Gabapentin, or Duloxetine.
4. Antidiabetic Pharmacotherapy & Guideline Algorithms
| Class | Major Drugs | Mechanism of Action | Clinical Advantages / Indications | Key Side Effects & Contraindications |
|---|---|---|---|---|
| Biguanides | Metformin | Decreases hepatic gluconeogenesis; increases peripheral insulin sensitivity | First-line agent; weight neutral; no hypoglycemia | GI upset, Vit B12 deficiency, Lactic Acidosis. Contraindicated if eGFR <30 mL/min/1.73 m² |
| SGLT2 Inhibitors | Empagliflozin, Dapagliflozin | Inhibits SGLT2 in proximal convoluted tubule → glucosuria | Proven Cardiorenal protection (reduces HF hospitalizations & CKD progression); weight loss | Mycotic genital infections, UTIs, Euglycemic DKA, volume depletion |
| GLP-1 Receptor Agonists | Semaglutide, Liraglutide, Dulaglutide | Incretin mimetic: glucose-dependent insulin secretion, slows gastric emptying | Major reduction in ASCVD MACE events; profound weight loss | Nausea, vomiting, pancreatitis risk, C-cell thyroid tumor risk (MEN2 contraindication) |
| DPP-4 Inhibitors | Sitagliptin, Linagliptin | Prevents degradation of endogenous GLP-1 | Weight neutral; low hypoglycemia risk; Linagliptin requires no renal dose adjustment | Pancreatitis, joint pain; Saxagliptin increases HF risk |
| Sulfonylureas | Glimepiride, Gliclazide | Closes K-ATP channels on pancreatic beta cells → insulin secretagogue | Potent glucose lowering; low cost | Hypoglycemia, weight gain |
| Thiazolidinediones | Pioglitazone | PPAR-gamma agonist; enhances peripheral insulin sensitivity | No hypoglycemia | Fluid retention/Edema, Contraindicated in Heart Failure (NYHA III/IV), bone fractures |
During the emergency management of a 24-year-old female presenting with Diabetic Ketoacidosis (arterial pH 7.12, blood glucose 480 mg/dL), her serum potassium is reported as 2.9 mEq/L. Which of the following is the most appropriate immediate action?
A 52-year-old asymptomatic male undergoes a routine health check. His Fasting Plasma Glucose is 134 mg/dL. A repeat Fasting Plasma Glucose three days later is 130 mg/dL. His HbA1c is 6.8%. How should this patient's glycemic status be classified according to ADA diagnostic criteria?
A 58-year-old Type 2 Diabetic patient with chronic kidney disease (eGFR 42 mL/min/1.73 m²) and heart failure with reduced ejection fraction (HFrEF) requires second-line add-on therapy after Metformin. Which class of antidiabetic medications provides the greatest reduction in heart failure hospitalizations and CKD progression?
Fundoscopic examination of a 60-year-old diabetic patient reveals microaneurysms, dot-and-blot hemorrhages, cotton-wool spots, and widespread retinal neovascularization. What is the correct clinical stage and recommended definitive treatment?